LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.

Lacey, Charles; Musa, Ahmed; Khalil, El Tahir; Younis, Brima; Osman, Mohamed; Wiggins, Rebecca; Keding, Ada; Kaye, Paul

Lacey, Charles; Musa, Ahmed; Khalil, El Tahir; Younis, Brima; Osman, Mohamed; Wiggins, Rebecca; Keding, Ada; Kaye, Paul.

Afiliação

Lacey C; York Biomedical Research Institute, University of York, UK, York, UK.
Musa A; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Khalil ET; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Younis B; Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
Osman M; York Biomedical Research Institute, University of York, UK, York, UK.
Wiggins R; York Biomedical Research Institute, University of York, UK, York, UK.
Keding A; York Trials Unit, University of York, UK, York, UK.
Kaye P; York Biomedical Research Institute, University of York, UK, York, UK.

Wellcome Open Res ; 7: 200, 2022.

Article em En | MEDLINE | ID: mdl-37252616

Palavras-chave

Leishmania; PKDL; RCT; Sudan

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Wellcome Open Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google